



SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : compliance@sudarshanpharma.com **Website :** www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) **CIN :** L51496MH2008PLC184997

SPIL/CS/SE/2024-2025/50

Date: 7th January, 2025

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Sub: Premises taken on rent for setting up new Research & Development formulation centre in Dehradun, Uttarakhand, India
Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('**SEBI Listing Regulations**'), we are pleased to inform you that the Company has entered into a Rent Agreement with M/s. Daundi Biological Private Limited to acquire premises for a period of 5 years commencing from 29th December 2024 to set up a new Research & Development formulation centre in the city of Dehradun, Uttarakhand, India.

It is expected to commence the operations of the formulation R&D Centre in the month of March, 2025.

This is for your information and record.

Thanks & Regards,

Yours faithfully,

For, **Sudarshan Pharma Industries Limited**


Hemal Mehta
Chairman & Managing Director